Material Event Form 8 K

Item 8.01.Other Events.

As previously reported, on July 26, 2024, CNS Pharmaceuticals, Inc. (the "Company") entered into a Sales Agreement (the "Agreement") with A.G.P./Alliance Global Partners ("A.G.P."). Pursuant to the terms of the Agreement, the Company originally was permitted to sell from time to time through A.G.P., as sales agent or principal, shares of the Company's common stock, par value $0.001 per share ("Common Stock") with initial aggregate sales price of up to $5.2 million (the "Shares"). On July 30, 2024, the Company increased the aggregate sales price of Shares that may be sold under the Agreement to $25.0 million (not including the original $5.2 million). As of July 30, 2024, the Company has sold 7,206,743 Shares pursuant to the Agreement for gross proceeds of approximately $5.19 million. As of July 30, 2024, the Company has 10,075,017 shares of common stock outstanding.

Any sale of Shares pursuant to the Agreement will be made under the Company's effective "shelf" registration statement (the "Registration Statement") on Form S-3 (File No. 333-279285), which became effective on May 17, 2024 and includes a base prospectus (the "Base Prospectus"), and under the related prospectus supplement (the "ATM Prospectus," and collectively with the Base Prospectus, the "Prospectus") filed with the Securities and Exchange Commission (the "SEC") dated July 26, 2024 as supplement on July 30, 2024. The $30.2 million of Common Stock that may be offered, issued, and sold under the ATM Prospectus is included in the $75,000,000 of securities that may be offered, issued, and sold by the Company under the Base Prospectus.